

New protocols/documents	Protocols recently updated	Document updates
<ul style="list-style-type: none"> <li>• <a href="#">ID 1918 - Basal cell carcinoma locally advanced or metastatic vismodegib</a></li> <li>• <a href="#">ID 3404 Acute lymphoblastic leukaemia blinatumomab</a></li> <li>• <a href="#">ID 3506 Acute lymphoblastic leukaemia dasatinib</a></li> <li>• <a href="#">ID 3535 High dose methotrexate-induced toxicity</a></li> <li>• <a href="#">ID 3379 - Breast metastatic ribociclib</a></li> <li>• <a href="#">ID 3363 - Glioblastoma recurrent lomustine</a></li> </ul>	<ul style="list-style-type: none"> <li>• <a href="#">ID 410 - Brain glioblastoma EBRT short course</a></li> <li>• <a href="#">ID 1615 Lymphoma GDP (gemcitabine dexamethasone cisplatin)</a></li> <li>• <a href="#">ID 1942 Acute promyelocytic leukaemia standard risk (chemotherapy free) treatment overview and protocols (ID 1941 and ID 1943)</a></li> <li>• <a href="#">ID 363 Chronic myeloid leukaemia dasatinib</a></li> <li>• <a href="#">ID 362 Chronic myeloid leukaemia imatinib</a></li> <li>• <a href="#">ID 1238 Chronic myeloid leukaemia nilotinib</a></li> <li>• <a href="#">ID 1428 - Genetic testing for heritable mutations in the multiple endocrine neoplasia (MEN) 1 gene</a></li> <li>• <a href="#">ID 192 - Risk management for multiple endocrine neoplasia (MEN) type 1</a></li> <li>• <a href="#">ID 230 - Mesothelioma cARBOplatin and pemetrexed</a></li> </ul>	<ul style="list-style-type: none"> <li>• <a href="#">Folinic acid (calcium folinate or Leucovorin®)</a>: low dose or high dose - evidence update.</li> <li>• <a href="#">ID 123 Immediate management of neutropenic fever</a> - Minor changes to definition of neutropenic fever. Changes to dose and frequency of antibiotics.</li> <li>• <a href="#">ID 177 Ifosfamide-induced encephalopathy</a> - Evidence update</li> <li>• <a href="#">ID 3176 - Multiple endocrine neoplasia type 1 (MEN1) - diagnostic criteria</a></li> </ul>
<h2 data-bbox="129 1075 510 1123">General updates</h2> <p data-bbox="129 1161 689 1426"><a href="#">Paclitaxel default diluent change:</a> The default diluent for paclitaxel is changing from glucose 5% to sodium chloride 0.9% to reflect clinical practice and longer stability data. Diluents are included on eviQ as defaults only and glucose 5% is still a suitable option.</p>		<h2 data-bbox="1491 1021 2074 1069">Discontinued/superseded</h2> <ul style="list-style-type: none"> <li>• <a href="#">ID 1662 Acute myeloid leukaemia induction 7-3 high dose SUPERSEDED DAUNOrubicin (cytarabine and DAUNOrubicin)</a> This protocol has been superseded and will no longer be updated/reviewed because it is not considered best practice for this patient population.</li> <li>• <a href="#">ID 1671 - Glioblastoma recurrent single agent lomustine</a></li> </ul>